217 related articles for article (PubMed ID: 11117248)
41. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience.
Cavdar C; Zeybel M; Atay T; Sifil A; Sanlidag C; Gulay Z; Camsari T
Adv Perit Dial; 2004; 20():62-6. PubMed ID: 15384797
[TBL] [Abstract][Full Text] [Related]
42. Topical Honey in the Management of Pediatric Peritoneal Dialysis Exit Sites.
Forbes TA; Shaw L; Quinlan C
Perit Dial Int; 2016 11-12; 36(6):684-687. PubMed ID: 27903852
[TBL] [Abstract][Full Text] [Related]
43. The CARI guidelines. Evidence for peritonitis treatment and prophylaxis: prophylaxis for exit site/tunnel infections using mupirocin.
Caring for Australians with Renal Impairment (CARI)
Nephrology (Carlton); 2004 Oct; 9 Suppl 3():S86-90. PubMed ID: 15469567
[No Abstract] [Full Text] [Related]
44. Resistance to mupirocin: no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients.
Vas SI; Conly J; Bargman JM; Oreopoulos DG
Perit Dial Int; 1999; 19(4):313-4. PubMed ID: 10507810
[No Abstract] [Full Text] [Related]
45. The impact of exit-site care and catheter design on the incidence of catheter-related infections.
Jones LL; Tweedy L; Warady BA
Adv Perit Dial; 1995; 11():302-5. PubMed ID: 8534730
[TBL] [Abstract][Full Text] [Related]
46. The impact of Propolis on catheter exit site infection and peritonitis in peritoneal Dialysis patients: a clinical trial.
Moghiseh L; Nobahar M; Ghorbani R; Sirafian S
BMC Nephrol; 2022 Dec; 23(1):408. PubMed ID: 36564743
[TBL] [Abstract][Full Text] [Related]
47. Exit site infections: systematic microbiologic and quality control are needed.
Freitas C; Rodrigues A; Carvalho MJ; Cabrita A
Adv Perit Dial; 2009; 25():26-31. PubMed ID: 19886313
[TBL] [Abstract][Full Text] [Related]
48. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients.
van Diepen AT; Tomlinson GA; Jassal SV
Clin J Am Soc Nephrol; 2012 Aug; 7(8):1266-71. PubMed ID: 22745277
[TBL] [Abstract][Full Text] [Related]
49. Erosion of the Silicone Peritoneal Dialysis Catheter with the Use of Gentamicin Cream at the Exit Site.
Gardezi AI; Schlageter KW; Foster DM; Astor BC; Chan MR; Waheed S
Adv Perit Dial; 2016; 32():15-18. PubMed ID: 28988584
[TBL] [Abstract][Full Text] [Related]
50. The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital.
Lim CT; Wong KS; Foo MW
Nephrol Dial Transplant; 2005 Aug; 20(8):1702-6. PubMed ID: 15855200
[TBL] [Abstract][Full Text] [Related]
51. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.
Crabtree JH; Hadnott LL; Burchette RJ; Siddiqi RA
Adv Perit Dial; 2000; 16():271-5. PubMed ID: 11045309
[TBL] [Abstract][Full Text] [Related]
52. Peritoneal catheter exit-site infections: predisposing factors, prevention and treatment.
Thodis E; Passadakis P; Ossareh S; Panagoutsos S; Vargemezis V; Oreopoulos DG
Int J Artif Organs; 2003 Aug; 26(8):698-714. PubMed ID: 14521167
[TBL] [Abstract][Full Text] [Related]
53. Peritoneal Dialysis Exit-Site Care Protocols in Portugal and Its Association with Catheter-Related Infections.
Ferreira AC; Fernandes V; Rodrigues A; Abreu CP; Pereira M; Guedes AM; Gomes AM; Cabrita A; Soares C; Pego C; Ferrer F; Bernardo I; Fernandes JC; Assunção J; Oliveira L; Amoedo M; Carvalho MJ; Branco P; Maia P; Chorão R; Castro R; Silva R; Sousa T; Mendes T;
Blood Purif; 2023; 52(4):366-372. PubMed ID: 36702111
[TBL] [Abstract][Full Text] [Related]
54. Significance, epidemiology, and prevention of peritoneal dialysis catheter infections.
Burkart JM
Perit Dial Int; 1996; 16 Suppl 1():S340-6. PubMed ID: 8728221
[TBL] [Abstract][Full Text] [Related]
55. [Prevention of peritonitis in patients with peritoneal dialysis].
Ivarsen PR; Møller JK; Povlsen JV
Ugeskr Laeger; 2006 Oct; 168(43):3714-7. PubMed ID: 17069736
[No Abstract] [Full Text] [Related]
56. Prevention of peritonitis in children on peritoneal dialysis.
Verrina E; Honda M; Warady BA; Piraino B
Perit Dial Int; 2000; 20(6):625-30. PubMed ID: 11216550
[TBL] [Abstract][Full Text] [Related]
57. Controversies in the management of infective complications of peritoneal dialysis.
Odudu A; Wilkie M
Nephron Clin Pract; 2011; 118(3):c301-8. PubMed ID: 21242698
[TBL] [Abstract][Full Text] [Related]
58. The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients.
Johnson DW; Clark C; Isbel NM; Hawley CM; Beller E; Cass A; de Zoysa J; McTaggart S; Playford G; Rosser B; Thompson C; Snelling P;
Perit Dial Int; 2009; 29(3):303-9. PubMed ID: 19458303
[TBL] [Abstract][Full Text] [Related]
59. Ofloxacin solution for persistent exit-site and tunnel infection in peritoneal dialysis.
Lew SQ; Gruia A
Perit Dial Int; 2013; 33(1):101-2. PubMed ID: 23349200
[No Abstract] [Full Text] [Related]
60. Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program.
Chen SS; Sheth H; Piraino B; Bender F
Perit Dial Int; 2016; 36(4):387-9. PubMed ID: 26634567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
